China Resources Pharmaceutical Group Goodwill

China Resources Pharmaceutical Group posts a goodwill of $28B as of June 2026. That compares with $27B in the prior-year period — up 5.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, China Resources Pharmaceutical Group's goodwill was $27B. The latest reading is $28B — a 5.7% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Goodwill is one piece of China Resources Pharmaceutical Group's financial statement story. At $28B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 3320.HK's goodwill usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; China Resources Pharmaceutical Group's other metric pages and overview cover the third.